FASN and metabolic dysfunction-associated steatotic liver disease: Considering that the TVB‐2664 (inhibitor of FASN) and Myriocin (autophagy activator) have been used in several clinical trials, including nonalcoholic fatty liver disease (NAFLD) and glioblastoma,[31, 32, 33, 34] our results were inspiring.